7th Congress of the European Academy of Neurology 2021

Five presentations underlining the safety and efficacy of CGRP MAb and gepant therapies were highlighted by Professor Peter Goadsby, CGRP Forum Co-Editor, during his end-of-conference summary of important migraine data at this year’s EAN. “It really is an exciting time to be in headache and there is so much opportunity for clinicians to engage with …

CGRP, amylin, VIP and PACAP all have potential as biomarkers for migraine diagnosis, target selection, personalised therapy and clinical trial endpoints, but methodological and other issues have so far prevented clear, consistent indications of which peptide would be most useful. “A single biomarker may not capture the variability of patients with migraine and, in the …

A novel composite treatment response score that evaluates significant changes in migraine frequency, headache frequency, severity of migraine attacks and migraine-related disability may aid patient management and expand access to effective preventive treatment. The score was tested in 78 patients with migraine undergoing erenumab treatment for periods of three (n=72), six (n=62) and 12 months …

In the absence of head-to-head studies, a network meta analysis of placebo-controlled trials of erenumab, fremanezumab and galcanezumab has shown that all three drugs provide comparable efficacy in patients with episodic migraine (EM) or chronic migraine (CM) who experienced multiple treatment failures. Compared with placebo, significantly greater median reductions in monthly migraine days (MMD) were …